Vaginal dryness, soreness or discomfort during sex can be the concern you intended to mention and never quite reach. A rushed appointment may focus on hot flashes while you leave wondering whether another symptom matters enough to bring up. You can put it on the agenda at the start, using whatever words feel comfortable.

You do not need to arrive with a diagnosis or a preferred estrogen product. Explain where the discomfort occurs, when you notice it and what has changed. That allows the clinician to consider menopausal tissue changes alongside other possibilities and to discuss an examination or treatment that fits the actual problem.

Describe the experience in your own language

Useful details include whether symptoms are outside, inside or difficult to locate; whether they occur during ordinary activities, urination or sexual activity; and whether there is itching, a new discharge or bleeding. Explain what the problem prevents you from doing. You do not have to be sexually active for discomfort to deserve attention.

The NHS description of vaginal dryness includes soreness, itching, pain and urinary concerns among possible symptoms. It also advises assessment when symptoms affect daily life or persist despite self-care. The source is UK guidance; its symptom descriptions can inform questions, while the available appointments, products and referral arrangements depend on your own healthcare setting.

Tell the clinician what you have tried and what else changed

Bring the names of lubricants, vaginal moisturizers, washes, prescription products and supplements you use. Mention recent medication changes and past cancer treatment if relevant. The NHS lists several possible contributors to dryness, including certain medicines, hormonal changes and perfumed products. That is a reason for a careful history, not a way to diagnose the cause from a product list. NHS source

Ask whether examination or testing would help clarify the symptoms. New discharge, pain or urinary complaints should not automatically be assigned to menopause. If you are anxious about an examination, say so and ask what it would involve, why it is proposed and how you can ask the clinician to pause.

Discuss relief options before settling on a prescription

Nonprescription lubricants and vaginal moisturizers are options to discuss, and local estrogen may be considered for appropriate menopausal vaginal symptoms. The Menopause Society's 2022 position statement describes low-dose vaginal estrogen and other therapies for bothersome symptoms when over-the-counter approaches have not provided adequate relief and systemic treatment is not otherwise indicated.

These options do different jobs and may not suit every person. Ask what benefit the clinician expects and how to recognize whether the proposed approach is helping. A general body lotion or skincare hormone cream should not be assumed to be a vaginal treatment. The NHS specifically distinguishes products intended for vaginal use from creams that may irritate the area. NHS source

Ask whether the treatment is local or systemic

If hot flashes and night sweats are also troublesome, mention them separately rather than hoping one vaginal product will cover everything. The FDA explains that systemic treatment and topical vaginal estrogen have different roles. It also lists vaginal rings in both categories, which makes the exact product name important.

For example, Estring's information identifies a vaginal-symptom indication, while Femring's label also includes vasomotor symptoms such as hot flashes. These are examples of different product identities, not recommendations to select or exchange rings. Ask the clinician to name the medicine and its intended target. For nighttime symptoms, our sleep and hot-flash guide prepares a separate treatment-goal discussion.

Lower exposure still calls for a medical history

A local treatment should not be described as automatically suitable or unable to enter the bloodstream. The Estring label revised April 2026 states that systemic absorption occurs, generally with lower exposure than systemic estrogen used for vasomotor symptoms. It also leaves uncertainty about how far systemic estrogen risks apply to that product. Estring source

Discuss prior breast or other hormone-sensitive cancer, unexplained bleeding and other relevant conditions before a treatment is chosen. If you already receive systemic hormones, make sure the clinician knows the complete regimen. For someone with a uterus, uterine protection needs to be considered in relation to the full systemic plan; do not infer a change to that plan from the addition of a local product. FDA source

Treat bleeding as information that needs assessment

Dryness can coexist with bleeding, but that does not establish why bleeding happened. The ACOG bleeding guide describes several possible causes and emphasizes reporting bleeding after menopause. Tell the clinician about spotting after sex or any new blood, even if the amount seems too small to count as a period.

Our bleeding-history guide helps organize the dates, amount and related symptoms. Do not delay reporting a concern while trying another product to see whether it disappears. An online service should be able to explain how a need for an examination or further investigation will be handled; convenient prescribing and access to an appropriate assessment are separate questions.

Make the follow-up practical and private

Ask when the clinician wants to hear how you are doing and how to report discomfort, application difficulties or a change in symptoms. Agree on the treatment goal in terms that matter to you, such as less soreness in daily life or greater comfort during intimacy. You can ask for sensitive follow-up messages to use a communication method you are comfortable with.

Our CoreAge Rx review and care comparison cover provider questions without deciding which medicine you should receive. Midlife Appointment is a participant in CoreAge Rx's promotional publishing network, so its leading placement is commercial. A useful appointment should produce an explanation of your options and a clear path to further care, regardless of which provider you use.

Read alongside the article

Sources & notes.

These sources provide provider descriptions or medical context. They do not replace an individual clinical assessment.

  1. NHS: Vaginal dryness ↗UK public health patient guidance · Checked 2026-09-27
  2. The 2022 hormone therapy position statement of The North American Menopause Society: published abstract ↗Professional society consensus statement abstract hosted by PubMed · Checked 2026-09-27
  3. FDA: Hormone Replacement Therapies Can Help Women with Bothersome Menopausal Symptoms ↗Federal patient and labeling guidance · Checked 2026-09-27
  4. Pfizer: Estring prescribing information, April 2026 revision ↗Manufacturer product labeling · Checked 2026-09-27
  5. DailyMed: Femring estradiol acetate vaginal ring label; record updated December 2025, prescribing information revised November 2023 ↗US National Library of Medicine hosted product labeling · Checked 2026-09-27
  6. ACOG: Perimenopausal Bleeding and Bleeding After Menopause ↗US professional society patient guidance · Checked 2026-09-27